“Developing an infectious disease diagnosis platform.”

Ionica Sciences is employing two established technologies in a the IonID platform for disease diagnosis (patent pending). IonID allows direct detection of antigens associated with difficult to diagnose diseases. The first application is Lyme disease, the fastest growing vector-borne disease in the US. Initial pre-clinical studies have produced sensitivity and specificity of >90%, significantly better than the 55% currently demonstrated by commercial Lyme assays. This platform is widely applicable, with interest from government funding agencies to apply this technology to COVID detection.
Ionica is led by a strong team, and their Chief Business Officer brought his previous startup to a successful exit.  

Sector(s): Healthcare, Diagnostics

Ionica Sciences Overview

Ionica Sciences Homepage    Ionica Sciences Linkedin Page

Year founded 2013
Headquarters Ithaca, NY, USA
No. of employees 3

Ionica Sciences Key Financials 

Amount raised on previous funding rounds $403,000
Net Income (if in parenthesis, Net Loss) – on last year reported
Cash and Equivalents – on last year reported

Ionica Sciences – Offering

SEC Filings

Equity Crowdfunding Platform SeedInvest
Investors accepted Any accreditation level (retail investors accepted), Only from the USA
SEC Regulation (for US startups) Reg CF, Reg D (506c)
Minimum investment accepted $1000

Ionica Sciences‘ Startup Strength Indicators

Founder(s) Past Success Stories Ionica’s Chief Business Officer, Dean Koch, was CEO and co-founder of Cervilenz, which was acquired by United Women’s Healthcare. Cervilenz developed a medical device for determining risk for preterm birth.
Notable investors The Global Lyme Alliance, the premier Lyme patient advocacy philanthropy, was the first investor in Ionica Sciences.
Notable customers/partners Global Lyme Alliance
Proprietary IP/Patents WO2016134214 A1 (PCT application; pending)
Revenues on Last Year Reported (year)
Back to Crowdfunding.Guide home
Important: CrowdFunding.Guide (the “Website”) is owned and managed by Lucid Ventures Ltd. (the “Company”). The information on the website is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal, or other competent advisers. The information contained on the Website is for general information purposes only. We are not licensed or registered as a securities broker or dealer, investment adviser, or funding portal with the U.S. Securities and Exchange Commission or any similar regulatory entity of any country or state. Nothing on this website constitutes an offer or solicitation to sell, buy or subscribe to any securities in any country or jurisdiction, and nothing in it is intended as investment advice or a recommendation to act in any way. We strongly urge you to consider the fact that investing in startups, real-estate projects or any other venture through equity crowdfunding involves substantial risks and may result in the loss of your entire investment. We recommend that you consult with a professional consultant before making investment decisions.
We rely on the startups and platforms featured on the Website to provide us with the information we present on the Website and on their commitment that the information they provide us is true. Additional information presented on the Website is collected from sources open to the general public such as company websites, Linkedin, and crowdfunding platforms. The Company has not conducted any Due Diligence process on any startup or other company or business mentioned or presented on the Website.
Articles and blog posts marked with the word “SPONSORED” are sponsored content and feature companies or businesses that are paying us for the publication and or additional Services, such as digital marketing, advisory services, advertising, etc. Information on the payments we receive for sponsored content can be found on our 17b Disclosure page.